amoxicillin
J01C - Beta-lactam antibacterials, penicillins
ATC J01CA04
Small molecule
approved 1974
Oral
Natural product
🧬 Cross-allergy: Penicillins
JFDA label: Penamox 1 G Tablets
Mechanism of Action
Inhibitor of Bacterial penicillin-binding protein — Bacterial penicillin-binding protein inhibitor
| Target | Action | Gene / class |
|---|---|---|
| Bacterial penicillin-binding protein efficacy | INHIBITOR |
Indications
Approved
- Ear, nose, and throat infections (pharyngitis/tonsillitis, otitis media, rhinosinusitis)
- Genitourinary tract infections
- Helicobacter pylori eradication
- Lower respiratory tract infections (including pneumonia)
- Pharyngitis and tonsillitis
- Skin and skin structure infections
Off-label
- Anthrax, inhalational post-exposure prophylaxis (documented susceptible organisms) (adults)
- Anthrax, inhalational post-exposure prophylaxis (documented susceptible organisms) (children)
- Community-acquired pneumonia (children)
- Erysipeloid
- Group A streptococcal pharyngitis (children)
- Infective endocarditis (prophylaxis)
- Lyme disease (excluding neurologic disease)
- Lyme neuroborreliosis
- Prophylaxis in patients with prosthetic joint implants undergoing dental procedures which produce bacteremia
- Prosthetic joint infection
Antimicrobial Spectrum
Expected / intrinsic spectrum (EUCAST breakpoints & labels) — not local resistance. Source: EUCAST v16 · curated · openfda-label.
Bacteria
| Organism | Activity | MIC |
|---|---|---|
| Anaerobes | Susceptible | 22.0 mg/L |
| Bacteroides fragilis | Active | — |
| Enterobacterales | Susceptible | 8.0 mg/L |
| Enterococcus faecalis | Susceptible | 4.0 mg/L |
| Enterococcus spp. | Susceptible | 41.0 mg/L |
| Escherichia coli | Susceptible | 8.0 mg/L |
| Haemophilus influenzae | Susceptible | 2.0 mg/L |
| Haemophilus influenzae | Susceptible | 0.001 mg/L |
| Helicobacter pylori | Susceptible | 0.125 mg/L |
| Listeria monocytogenes | Susceptible | 1.0 mg/L |
| Moraxella catarrhalis | Susceptible | -1.0 mg/L |
| Pasteurella multocida | Susceptible | 1.0 mg/L |
| Proteus mirabilis | Active | — |
| Staphylococcus aureus | Active | — |
| Staphylococcus epidermidis | Active | — |
| Staphylococcus saprophyticus | Active | — |
| Streptococcus pneumoniae | Susceptible | 0.5 mg/L |
| Streptococcus pneumoniae | Susceptible | 0.06 mg/L |
| Streptococcus pyogenes | Susceptible | 0.25 mg/L |
| Viridans group streptococci | Susceptible | 0.5 mg/L |
| Enterococcus faecalis | Resistant | 4.0 mg/L |
| Escherichia coli | Resistant | 8.0 mg/L |
| Haemophilus influenzae | Resistant | 2.0 mg/L |
| Streptococcus pneumoniae | Resistant | 2.0 mg/L |
Class profile
| gramStatus | Both |
|---|---|
| spectrumBreadth | Moderate |
| atypicalCoverage | No |
| isBactericidal | 1 |
| moaCategory | Cell wall synthesis inhibitor (beta-lactam, PBP binding) |
| pdIndex | Time-dependent |
| postAntibioticEffect | None |
| mrsaCoverage | 0 |
| resistanceMechanisms | Beta-lactamase production,PBP mutations (PBP2a in MRSA),Reduced permeability |
Contraindications
Source: Lexicomp
- Additional contraindications (not in US labeling): Infectious mononucleosis (suspected or confirmed) Absolute
- Serious hypersensitivity to amoxicillin (eg, anaphylaxis, Stevens-Johnson syndrome) or to other beta-lactams, or any component of the formulation Absolute
Adverse Reactions
Very Common >10%Common 1–10%Uncommon 0.1–1%
Rare 0.01–0.1%Very Rare <0.01%Not Known
Cardiac disorders (1)
Not Known Hypersensitivity angiitis
Nervous system disorders (9)
Not Known Agitation · anxiety · behavioral changes · confusion · dizziness · headache · hyperactivity (reversible) · insomnia · seizure
Hepatobiliary disorders (6)
Uncommon Elevated liver enzymes
Not Known Cholestatic hepatitis · cholestatic jaundice · hepatitis (acute cytolytic) · increased serum ALT · increased serum AST
Renal and urinary disorders (1)
Not Known Crystalluria
Blood and lymphatic system disorders (7)
Not Known Agranulocytosis · anemia · eosinophilia · hemolytic anemia · leukopenia · thrombocytopenia · thrombocytopenia purpura
Immune system disorders (3)
Rare Allergic reaction (IgE-mediated urticaria/anaphylaxis)
Not Known Anaphylaxis · Serum sickness-like reaction
Gastrointestinal disorders (10)
Common Diarrhoea · Nausea
Not Known Dental discoloration (brown, yellow, or gray; rare) · diarrhea · hemorrhagic colitis · melanoglossia · mucocutaneous candidiasis · nausea · pseudomembranous colitis · vomiting
Skin and subcutaneous tissue disorders (9)
Very Common Maculopapular rash (high rate in EBV/CMV)
Common Skin rash
Not Known Acute generalized exanthematous pustulosis · erythema multiforme · erythematous maculopapular rash · exfoliative dermatitis · Stevens-Johnson syndrome · toxic epidermal necrolysis · urticaria
Infections and infestations (1)
Uncommon Clostridioides difficile colitis
Dosing
Source: Lexicomp
Note: Unless otherwise specified, all dosing recommendations based on immediate release product formulations. Usual dosage range: Oral: Mild or moderate infection: 250 mg every 8 hours or 500 mg every 12 hours Mild or moderate infection (lower respiratory tract): 500 mg every 8 hours or 875 mg every 12 hours Severe infection (as step-down therapy): 500 mg every 8 hours or 875 mg every 12 hours Extended-release: 775 mg once daily Indication-specific dosing: Anthrax, inhalational postexposure prophylaxis (CDC recommendations) (off-label use): Oral: 1,000 mg every 8 hours (Hendricks [CDC 2014]). Note: Use only if isolates of the specific B. anthracis are sensitive to amoxicillin (MIC ≤0.125 mcg/mL); may be administered to pregnant and breast-feeding women. Duration of antibiotic postexposure prophylaxis (PEP) is 60 days whether a patient is vaccinated, partially vaccinated, or unvaccinated (Hendricks [CDC 2014]). Ear, nose, throat, genitourinary tract, or skin/skin structure infections: Note: IDSA guidelines recommend amoxicillin-clavulanate as preferred first-line treatment of acute bacterial rhinosinusitis (ABRS) (IDSA [Chow 2012]); AAO-HNS guidelines for adult sinusitis recommend either amoxicillin or amoxicillin-clavulanate as initial first-line therapy of ABRS, with consideration given for amoxicillin-clavulanate instead of amoxicillin in certain patients (eg, moderate to severe ABRS symptoms, antibiotic use in past month, high prevalence of resistant bacteria in community, history of recurrent ABRS, presence of comorbidities) (AAO-HNS [Rosenfeld 2015]). Mild-to-moderate: Oral: 500 mg every 12 hours or 250 mg every 8 hours Severe: Oral: 875 mg every 12 hours or 500 mg every 8 hours Tonsillitis and/or pharyngitis: Oral: Extended release: 775 mg once daily for 10 days Endocarditis, prophylaxis (off-label use): Oral: 2 g 30 to 60 minutes before procedure. Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in who underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA. Erysipeloid (off-label use): Oral: 500 mg 3 times daily for 7 to 10 days (IDSA [Stevens 2014]) Helicobacter pylori eradication: Oral: American College of Gastroenterology guidelines (Chey 2007; Chey 2017): Clarithromycin triple therapy: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily plus a standard-dose or double-dose proton pump inhibitor; continue regimen for 14 days. Note: Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates ≥15%, eradication rates with clarithromycin-based regimens ≤85%) (ACG [Chey 2017]; Fallone 2016). Concomitant regimen: 1,000 mg twice daily in combination with clarithromycin 500 mg twice daily, and eit
(For additional information see "Amoxicillin: Pediatric drug information") Note: Unless otherwise specified, all pediatric dosing recommendations based on immediate release product formulations (oral suspension, chewable tablet, tablet, and capsule). Usual dosage range: Mild to moderate infection: Infants ≤3 months: Oral: 25 to 50 mg/kg/day in divided doses every 8 hours (Red Book [AAP 2015]). Note: Manufacturer's labeling recommends a maximum daily dose of 30 mg/kg/day divided into 2 doses per day for this age group. Infants >3 months, Children, and Adolescents (AAP recommendations (Red Book [AAP 2015]): Oral: 25 to 50 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose Manufacturer's labeling: Oral: 20 to 40 mg/kg/day in divided doses every 8 hours (maximum dose: 500 mg/dose) or 25 to 45 mg/kg/day in divided doses every 12 hours (maximum dose: 875 mg/dose) Children, and Adolescents (≥40 kg): Refer to adult dosing. Severe infection (as step-down therapy): Infants, Children, and Adolescents: Oral: 80 to 100 mg/kg/day in divided doses every 8 hours; maximum dose: 500 mg/dose for most indications (Red Book [AAP 2015]) Indication-specific dosing: Anthrax (off-label use): Cutaneous, without systemic involvement: Children and Adolescents: Oral: 75 mg/kg/day in 3 divided doses. Maximum dose: 1,000 mg/dose. Duration of therapy: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related exposure (AAP [Bradley 2014]). Inhalational, postexposure prophylaxis: Children and Adolescents: Oral: 75 mg/kg/day in divided doses every 8 hours for 60 days after exposure; maximum dose: 1,000 mg/dose (AAP [Bradley 2014]). Catheter (peritoneal dialysis), exit-site or tunnel infection (off-label use): Infants, Children, and Adolescents: Oral: 10 to 20 mg/kg once daily; maximum dose: 1,000 mg/dose (Warady [ISPD 2012]) Endocarditis, prophylaxis (off-label use): Infants, Children, and Adolescents: Oral: 50 mg/kg 1 hour before procedure (maximum dose: 2,000 mg/dose) (Wilson 2007) Helicobacter pylori eradication: Children and Adolescents: Oral: 50 mg/kg/day in 2 divided doses for 10 to 14 days; maximum daily dose: 2,000 mg/day. Administer in combination with a proton pump inhibitor or bismuth subsalicylate and at least one other antibiotic (clarithromycin and/or metronidazole) (NASPGHAN/ESPGHAN [Koletzko 2011]). Lyme disease (off-label use): Infants, Children, and Adolescents: Oral: 50 mg/kg/day divided every 8 hours (maximum dose: 500 mg/dose) (Halperin 2007; Wormser 2006) Otitis media, acute: Infants ≥2 months and Children: Oral: 80 to 90 mg/kg/day divided every 12 hours; variable duration of therapy, if Red Book [AAP 2015]); a maximum dose is not provided in the Guidelines for The Diagnosis and Management of Acute Otitis Media (AAP [Lieberthal 2013]); however, some experts suggest a maximum daily dose of 4,000 mg/day for high-dose amoxicillin therapy (Bradley 2015). Peritonitis, prophylaxis (for patients receiving peritoneal
Refer to adult dosing.
Adults: Oral: Immediate-release: Note: Avoid immediate-release 875 mg tablet in patients with GFR GFR ≥30 mL/minute: No dosage adjustment necessary. GFR 10 to 30 mL/minute: 250 to 500 mg every 12 hours GFR Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 250 to 500 mg every 24 hours; administer after dialysis on dialysis days (Aronoff 2007) Extended-release: CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). CrCl Hemodialysis: Not recommended. Infants, Children, and Adolescents: Oral: Immediate-release: There are no dosage adjustments provided in the manufacturer’s labeling; however, the following recommendations have been used by some clinicians (Aronoff 2007): Mild to moderate infection: Dosing based on 25 to 50 mg/kg/day divided every 8 hours: GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary. GFR 10 to 29 mL/minute/1.73 m2: 8 to 20 mg/kg/dose every 12 hours GFR 2: 8 to 20 mg/kg/dose every 24 hours Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 8 to 20 mg/kg/dose every 24 hours; give after dialysis. Peritoneal dialysis: 8 to 20 mg/kg/dose every 24 hours. Severe infection (high dose): Dosing based on 80 to 90 mg/kg/day divided every 12 hours: GFR ≥30 mL/minute/1.73 m2: No dosage adjustment necessary. GFR 10 to 29 mL/minute/1.73 m2: 20 mg/kg/dose every 12 hours; do not use the 875 mg tablet. GFR 2: 20 mg/kg/dose every 24 hours; do not use the 875 mg tablet. Hemodialysis: Moderately dialyzable (20% to 50%); ~30% removed by 3-hour hemodialysis: 20 mg/kg/dose every 24 hours; give after dialysis. Peritoneal dialysis: 20 mg/kg/dose every 24 hours Extended-release: Children ≥12 years and Adolescents: CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). CrCl Hemodialysis: Not recommended.
There are no dosage adjustments provided in the manufacturer’s labeling.
Warnings & Precautions
Source: Lexicomp
Anaphylactic/hypersensitivity reactions
Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, including amoxicillin, especially with a history of beta-lactam hypersensitivity (including severe reactions with cephalosporins) and/or a history of sensitivity to multiple allergens.
Superinfection
Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment. Disease-related concerns:
Infectious mononucleosis
A high percentage of patients with infectious mononucleosis develop an erythematous rash during amoxicillin therapy; avoid use in these patients.
Renal impairment
Use with caution in patients with renal impairment; dosage adjustment recommended in patients with GFR Concurrent drug therapy issues:
Drug-drug interactions
Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Dosage form specific issues:
Benzyl alcohol and derivatives
Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.
Chewable tablets
May contain phenylalanine; see manufacturer’s labeling.
Pregnancy & Lactation
Pregnancy
FDA category B
Safe
First-line antibiotic for most infections in pregnancy. Part of H. pylori eradication when needed
Lactation
RID 0.15%
Amoxicillin is excreted in breast milk (Kafetzis 1981). The relative infant dose (RID) of amoxicillin is 0.15% to 0.54% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of 25 to 90 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is 25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest average milk concentration (0.9 mcg/mL), the estimated daily infant dose via b
Monitoring
| Efficacy | Culture and susceptibility testing; clinical resolution (temperature, WBC, CRP, procalcitonin) |
|---|---|
| Toxicity | Renal function (dose adjustment in renal impairment); hepatic function for hepatically cleared agents; signs of C. difficile infection (diarrhoea) |
| Clinical pearl | Culture results guide de-escalation to narrower-spectrum therapy. Review antibiotic appropriateness at 48–72 h (antimicrobial stewardship). |
| Counseling | Complete the full course. Report persistent diarrhoea, rash, or lack of improvement after 48–72 h. |
Chemistry & Properties
| Formula | C16H19N3O5S |
|---|---|
| Molecular weight | 365.41 g/mol |
| IUPAC name | (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| CAS | 26787-78-0 |
| PubChem CID | 33613 |
| InChIKey | LSQZJLSUYDQPKJ-NJBDSQKTSA-N |
| logP | 0.02 (XLogP -2.0) |
| Polar surface area | 132.96 Ų |
| H-bond acceptors / donors | 6 / 4 |
| Drug-likeness (QED) | 0.55 |
| Lipinski violations | 0 |
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)OBiology & Pharmacokinetics
Pharmacokinetics
| BBB penetrant | No |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP2C19 | Substrate | — |
Transporters
BCRP (Inhibitor)BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP4 (Inhibitor)OAT1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)PEPT1 (Inhibitor)PEPT2 (Inhibitor)MDR1 (Substrate)OAT (Substrate)OAT1 (Substrate)OAT2 (Substrate)OAT3 (Substrate)P-gp (Substrate)PEPT1 (Substrate)PEPT2 (Substrate)
Drug–drug interactions (33, DDInter)
| Interacting drug | Severity | Management |
|---|---|---|
| Methotrexate | major | |
| Typhoid vaccine (live) | major | |
| Vibrio cholerae CVD 103-HgR strain live antigen (live) | major | |
| Anisindione | moderate | |
| Balsalazide | moderate | |
| Bifidobacterium longum infantis | moderate | |
| Demeclocycline | moderate | |
| Dicoumarol | moderate | |
| Doxycycline | moderate | |
| Entecavir | moderate | |
| Estradiol | moderate | |
| Ethinylestradiol | moderate | |
| Indium In-111 oxyquinoline | moderate | |
| Iodide I-123 | moderate | |
| Iodide I-131 | moderate | |
| Lactobacillus acidophilus | moderate | |
| Mestranol | moderate | |
| Minocycline | moderate | |
| Mycophenolate mofetil | moderate | |
| Mycophenolic acid | moderate | |
| Oxytetracycline | moderate | |
| Pemetrexed | moderate | |
| Picosulfuric acid | moderate | |
| Sarecycline | moderate | |
| Tetracycline | moderate | |
| Warfarin | moderate | |
| Allopurinol | minor | |
| Amiloride | minor | |
| Azithromycin | minor | |
| Clarithromycin | minor | |
| Erythromycin | minor | |
| Probenecid | minor | |
| Troleandomycin | minor |
Registered Products (144)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| MOXILEN CAP | Capsule 500 mg | 16 cap pack varies | Khoury Drug Store | 0.790 |
| Amoclan 600 vials | Vial (as Sodium)500 mg, 100 mg | 1 pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 0.960 |
| MOXILEN CAP | Capsule 500 mg | 20 cap pack varies | Khoury Drug Store | 0.980 |
| Amoxil Forte Suspension | Suspension 250 mg/5 ml | 100 ml | Suleiman Tannous & Sons Co. Ltd | 0.990 |
| Amoxil Suspension | Suspension 125 mg/5 ml | 100 ml | Suleiman Tannous & Sons Co. Ltd | 1.000 |
| Moxiram Cap | Capsule 250 mg | 16 cap pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 1.180 |
| Amoxil Caps. | Capsule 250 mg | 20 cap | Suleiman Tannous & Sons Co. Ltd | 1.200 |
| Amoxil Caps. | Capsule 500 mg | 20 cap | Suleiman Tannous & Sons Co. Ltd | 1.200 |
| Ramoclav-156 suspension | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 60 ml pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 1.270 |
| Julphamox 125mg/5ml Susp. | Suspension 125 mg/5 ml | 100 ml | Professional Drug Store | 1.280 |
| Amoxydar G.F.SUSP.125mg/5ml | Suspension 125 mg/5 ml | 100 ml | Dar Al Dawa Development and Investment Co Ltd/Jordan | 1.320 |
| OSPAMOX 250 SUSP | Suspension 250 mg/5 ml | 60 ml pack varies | Nabulsi Drug Store | 1.450 |
| Penamox 250 Suspension | Suspension (as trihydrate) 250 mg/5 ml | 60 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 1.450 |
| Moxiram-250 capsule | Capsule 250 mg | 20 cap pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 1.480 |
| Moxiram-500 capsule | Capsule 500 mg | 20 cap pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 1.480 |
| Moxiclav | Vial 1000 mg, 200 mg | 1 vial pack varies | Khoury Drug Store | 1.510 |
| Amoclan 1200 vials | Vial (as Sodium)1000 mg, as potassium clavulanate 200 mg | 1 vial pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 1.790 |
| Klavox Susp. | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml | Regional Drug Store | 1.790 |
| Koact | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml | AL Rahma Drug Store | 1.790 |
| Megamox Susp | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml | IBN CINA DRUG STORE | 1.790 |
| Amoxydar Forte | Suspension 250 mg/5 ml | 100 ml | Dar Al Dawa Development and Investment Co Ltd/Jordan | 1.850 |
| Curam | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml | Nabulsi Drug Store | 1.850 |
| Moxiclav Sus | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml | Khoury Drug Store | 1.850 |
| Moxiram-125 suspension | Suspension 125 mg/5 ml | 100 ml | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 1.850 |
| Origaram | Suspension 250 mg/5 ml | 100 ml | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 1.850 |
| Julphamox 250mg/5ml Susp. | Suspension 250 mg/5 ml | 100 ml | Professional Drug Store | 2.010 |
| Moxilen Forte Susp | Suspension 250 mg/5 ml | 100 ml | Khoury Drug Store | 2.010 |
| Penamox | Suspension 500 mg/5 ml | 60 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.030 |
| Flumox 250mg Dry Susp | Suspension (as Trihydrate) 125 mg/5 ml, (as Monohydrate) 125 mg/5 ml | 100 ml | AL-Faiasel Drug Store | 2.080 |
| Moxiram-250 suspension | Suspension 250 mg/5 ml | 100 ml | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 2.090 |
| Ultramox Forte Suspension | Suspension 250 mg/5 ml | 100 ml | The Arab Pharmaceutical Manufactruing Co. | 2.110 |
| Amoclan Suspension | Suspension (as trihydrate) 125 mg/5 ml, (as potassium)31.25 mg/5 ml | 100 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.120 |
| Clavar | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml | The Arab Pharmaceutical Manufacturing PSC/Salt | 2.120 |
| Penamox 500 Capsules | Capsule (as Trihydrate)500 mg | 12 cap | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.120 |
| Ramoclav-156 suspension | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 2.120 |
| Amoxydar Caps. | Capsule 250 mg | 16 cap pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 2.140 |
| Amoclan BID | Suspension 400 mg/5 ml, 57 mg/5 ml | 35 ml pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.150 |
| Amoxapen | Tablet 500 mg | 20 tab | JAWEDA INT. DRUD STORE | 2.190 |
| Curam | Vial 2000 mg, 200 mg | one vial | Nabulsi Drug Store | 2.240 |
| OSPAMOX 375 SUSP | Suspension 375 mg/5 ml | 60 ml pack varies | Nabulsi Drug Store | 2.320 |
| Hymox Susp. | Suspension 250 mg/5 ml | 100 ml | Shawi & Rushedat Drug Store | 2.420 |
| OSPAMOX | Suspension 250 mg/5 ml | 100 ml pack varies | Nabulsi Drug Store | 2.420 |
| Penamox 250 Suspension | Suspension (as trihydrate)250 mg/5 ml | 100 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.420 |
| Ultramox Forte Cap | Capsule (as Trihydrate) 500 mg | 2x8 pack varies | The Arab Pharmaceutical Manufactruing Co. | 2.500 |
| Augmentin 156 Susp. | Suspension 125 mg/5 ml, 31.25 mg/5 ml | 100 ml | Suleiman Tannous & Sons Co. Ltd | 2.550 |
| Amoxydar Caps. | Capsule 250 mg | 20 cap pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 2.580 |
| Klavox Tab | Tablet 250 mg, 125 mg | 20 tab | Shawi & Rushedat Drug Store | 2.680 |
| Koact | Tablet 250 mg, 125 mg | 20 tab | AL Rahma Drug Store | 2.680 |
| Amoclan Forte Suspension | Suspension (as Trihydrate)250 mg/5 ml, (as potassium) 62.5 mg/5 ml | 60 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.770 |
| Ramoclav-312 suspension | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 60 ml pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 2.770 |
| Megamox Tab | Tablet 875 mg, 125 mg | 10 tab | IBN CINA DRUG STORE | 2.810 |
| Amoclan Forte Tablets | Tablet (as trihydrate) 500 mg, (as potassium) 125 mg | 12 tab pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.900 |
| Penamox | Tablet (as trihydrate) 1 g | 10 tab | Hikma Pharmaceuticals Co.Ltd/Jordan | 2.900 |
| Ramoclav-625 tablets | Tablet Anhydrous 500 mg, 125 mg | 12 tab pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 2.900 |
| Moxiclav Tab | Tablet 250 mg, 125 mg | 20 tab | Khoury Drug Store | 2.920 |
| Klavox Susp | Suspension 200 mg, 28 mg/5 ml | 70 ml | Regional Drug Store | 2.970 |
| Klavox Susp | Suspension 400 mg/5 ml, 57 mg/5 ml | 70 ml | Shawi & Rushedat Drug Store | 2.990 |
| Koact | Tablet 500 mg, 125 mg | 15 tab | AL Rahma Drug Store | 2.990 |
| Amoxydar F.C.T | Tablet 1 g | 10 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.000 |
| Moxiram | Tablet 1 g | 10 tab | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 3.000 |
| Ultramox Forte Cap | Capsule (as Trihydrate) 500 mg | 2x10 pack varies | The Arab Pharmaceutical Manufactruing Co. | 3.130 |
| Amoxydar Forte Caps. | Capsule 500 mg | 16 cap pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.140 |
| Julphamox 500mg Cap. | Capsule 500 mg | 20 cap pack varies | Professional Drug Store | 3.210 |
| Klavox Susp. | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | Shawi & Rushedat Drug Store | 3.210 |
| Amoclan BID | Suspension 200 mg/5 ml, 28.5 mg/5 ml | 70 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 3.230 |
| CLAVODAR 200/28.5 SUSPENSION | Suspension 200 mg/5 ml, 28.5 mg | 70 ml | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.230 |
| Curam | Suspension 400 mg/5 ml, 57 mg/5 ml | 70 ml pack varies | Nabulsi Drug Store | 3.260 |
| Curam | Tablet 500 mg, 125 mg | 15 tab pack varies | Nabulsi Drug Store | 3.260 |
| OSPAMOX 750 F.C TAB | Film-Coated Tablet 750 mg | 12 tab pack varies | Nabulsi Drug Store | 3.260 |
| CLAVODAR 625 TABLETS | Tablet 500 mg, 125 mg | 14 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.390 |
| Moxiclav F.C Tab | Film-Coated Tablet 500 mg, 125 mg | 16 tab pack varies | Khoury Drug Store | 3.460 |
| Penamox | Tablet (as Trihydrate) 1 g | 12 tab pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 3.480 |
| Koact | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | AL Rahma Drug Store | 3.490 |
| Penamox 500 Capsules | Capsule (as Trihydrate) 500 mg | 20 cap pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 3.540 |
| Amoxydar F.C.T | Tablet 1 g | 12 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.600 |
| Amoclan Forte Tablets | Tablet (as trihydrate) 500 mg, (as potassium) 125 mg | 15 tab pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 3.630 |
| Ramoclav-625 tablets | Tablet Anhydrous 500 mg, 125 mg | 15 tab pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 3.630 |
| Amoclan Tablets | Tablet (as trihydrate) 250 mg, (as potassium) 125 mg | 20 tab | Hikma Pharmaceuticals Co.Ltd/Jordan | 3.640 |
| Clavar 375mg Tab Tablets | Tablet 250 mg, 125 mg | 20 tab | The Arab Pharmaceutical Manufacturing PSC/Salt | 3.640 |
| Flumox | Capsule 250 mg, 250 mg | 16 cap | AL-Faiasel Drug Store | 3.640 |
| Ramoclav-375 tablets | Tablet Anhydrous 250 mg, 125 mg | 20 tab | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 3.640 |
| Amoxibel | Tablet 500 mg | 20 tab | MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN | 3.650 |
| Klamoks Bid Fort | Solution 400 mg, 57 mg | 70 ml | Itqan Pharmaceutical Industries/Jordan | 3.700 |
| Amoxydar Forte Caps. | Capsule 500 mg | 20 cap pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 3.770 |
| Augmentin Tab | Tablet 250 mg, 125 mg | 20 tab | Suleiman Tannous & Sons Co. Ltd | 3.830 |
| OSPAMOX 375 SUSP | Suspension 375 mg/5 ml | 100 ml pack varies | Nabulsi Drug Store | 3.860 |
| Curam | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | Nabulsi Drug Store | 3.910 |
| Megamox Tab | Tablet 125 mg, 875 mg | 14 tab | IBN CINA DRUG STORE | 3.930 |
| Klamoks BID Tab | Tablet 875 mg, 125 mg | 10 tab | Itqan Pharmaceutical Industries/Jordan | 3.940 |
| Augmentin 457 Susp. | Suspension 400 mg/5 ml, 57 mg/5 ml | 70 ml | Suleiman Tannous & Sons Co. Ltd | 4.010 |
| Moxiclav Forte Sus | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | Khoury Drug Store | 4.070 |
| Augmentin Infant Drops 62.5mg/ml Powder for oral suspension | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 20 ml | Suleiman Tannous & Sons Co. Ltd | 4.080 |
| Amoclan BID | Suspension 400 mg/5 ml, 57 mg/5 ml | 70 ml pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 4.100 |
| CLAVODAR 400/57 Forte | Suspension 400 mg/5 ml, 57 mg/5 ml | 70 ml | Dar Al Dawa Development and Investment Co Ltd/Jordan | 4.100 |
| Julmentin 2X | Solution 400 mg, 57 mg | 70 ml | Professional Drug Store | 4.110 |
| Moxiclav | Tablet 875 mg, 125 mg | 14 tab | Khoury Drug Store | 4.200 |
| KOACT | Tablet 875 mg, 125 mg | 15 tab | AL Rahma Drug Store | 4.210 |
| Curam Tab | Tablet 875 mg, 125 mg | 10 tab pack varies | Nabulsi Drug Store | 4.250 |
| Curam | Tablet 500 mg, 125 mg | 20 tab pack varies | Nabulsi Drug Store | 4.340 |
| Moxiclav F.C Tab | Film-Coated Tablet 500 mg, 125 mg | 20 tab pack varies | Khoury Drug Store | 4.340 |
| OSPAMOX 750 F.C TAB | Film-Coated Tablet 750 mg | 16 tab pack varies | Nabulsi Drug Store | 4.340 |
| Augmentin 312 Susp. | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | Suleiman Tannous & Sons Co. Ltd | 4.590 |
| Hymox Cap | Capsule 500 mg | 20 cap | Regional Drug Store | 4.600 |
| Amoclan Forte Suspension | Suspension (as Trihydrate) 250 mg/5 ml, (as potassium) 62.5 mg/5 ml | 100 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 4.620 |
| Clavar Forte | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | The Arab Pharmaceutical Manufacturing PSC/Salt | 4.620 |
| Megamox susp. | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | IBN CINA DRUG STORE | 4.620 |
| Ramoclav-312 suspension | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 4.620 |
| Amoclan BID Tablets | Tablet 875 mg, 125 mg | 10 tab pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 4.630 |
| Julmentin Forte 312mg/5ml Susp. | Suspension 250 mg/5 ml, 62.5 mg/5 ml | 100 ml | Professional Drug Store | 4.630 |
| Curam | Suspension 400 mg/5 ml, 57 mg/5 ml | 100 ml pack varies | Nabulsi Drug Store | 4.660 |
| Amoclan Bid | Suspension 600 mg/5 ml, 42.9 mg/5 ml | 75 ml | Hikma Pharmaceuticals Co.Ltd/Jordan | 4.700 |
| Amoxydar F.C.T | Tablet 1 g | 16 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 4.800 |
| Amoclan Forte Tablets | Tablet (as trihydrate) 500 mg, (as potassium) 125 mg | 20 tab pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 4.840 |
| CLAVODAR 625 TABLETS | Tablet 500 mg, 125 mg | 20 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 4.840 |
| Clavar Forte | Tablet 500 mg, 125 mg | 20 tab | The Arab Pharmaceutical Manufacturing PSC/Salt | 4.840 |
| Ramoclav | Tablet Anhydrous 500 mg, 125 mg | 20 tab pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 4.840 |
| Julmentin ES Susp | Suspension 600 mg/5 ml, 42.9 mg/5 ml | 100 ml | Professional Drug Store | 4.880 |
| CLAVODAR | Tablet 875 mg, 125 mg | 10 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 4.960 |
| Curam Tab | Tablet 875 mg, 125 mg | 14 tab pack varies | Nabulsi Drug Store | 5.050 |
| OSPAMOX 1000 F.C Tab | Film-Coated Tablet 1000 mg | 12 tab pack varies | Nabulsi Drug Store | 5.170 |
| Penamox | Tablet (as Trihydrate) 1 g | 18 tab pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 5.220 |
| Augmentin 1 gm FC Tablet | Film-Coated Tablet 875 mg, 125 mg | 14 tab | Suleiman Tannous & Sons Co. Ltd | 5.610 |
| Augmentin Tab | Tablet 500 mg, 125 mg | 20 tab | Suleiman Tannous & Sons Co. Ltd | 5.690 |
| Clavodar ES Powder For Oral Susp | Suspension 600 mg/5 ml, 42.9 mg/5 ml | 100 ml | Dar Al Dawa Development and Investment Co Ltd/Jordan | 6.270 |
| Amoclan BID Tablets | Tablet 875 mg, 125 mg | 14 tab pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 6.490 |
| Klavox Tab | Tablet 875 mg, 125 mg | 14 tab | Shawi & Rushedat Drug Store | 6.490 |
| Penamox | Tablet (as rrihydrate) 1 g | 24 tab | Hikma Pharmaceuticals Co.Ltd/Jordan | 6.610 |
| OSPAMOX 1000 F.C Tab | Film-Coated Tablet 1000 mg | 16 tab pack varies | Nabulsi Drug Store | 6.890 |
| CLAVODAR | Tablet 875 mg, 125 mg | 14 tab pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 6.940 |
| Augmentin ES-600 | Solution 600 mg, 42.9 mg | 100 ml | Suleiman Tannous & Sons Co. Ltd | 6.970 |
| Amoclan Bid 400/57 Chewable Tab | Chewable Tablet 400 mg, 57 mg | 18 Chew Tab | Hikma Pharmaceuticals Co.Ltd/Jordan | 7.480 |
| Julmentin 2X | Tablet 875 mg, 125 mg | 15 tab | Professional Drug Store | 7.540 |
| Amoclan 600mg vials | Vial (as Sodium)500 mg, 100 mg | 10 vial pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 8.750 |
| MOXILEN CAP | Capsule 500 mg | 200 cap pack varies | Khoury Drug Store | 8.840 |
| Moxiclav | Vial 1000 mg, 200 mg | 10 vial pack varies | Khoury Drug Store | 13.630 |
| Amoclan 1200 vials | Vial (as Sodium)1000 mg, as potassium clavulanate 200 mg | 10 vial pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 16.300 |
| Amoxydar Caps. | Capsule 250 mg | 500 cap pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 43.310 |
| Ultramox Forte Cap | Capsule (as Trihydrate) 500 mg | 50x8 pack varies | The Arab Pharmaceutical Manufactruing Co. | 53.130 |
| Moxiram Cap | Capsule 250 mg | 1000 cap pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 62.690 |
| Moxiram-500 capsule | Capsule 500 mg | 1000 cap pack varies | AL-RAM PHARMA.INDUS.CO.LTD/JORDAN | 62.900 |
| Amoxydar Forte Caps. | Capsule 500 mg | 500 cap pack varies | Dar Al Dawa Development and Investment Co Ltd/Jordan | 68.780 |
| Julphamox 500mg Cap. | Capsule 500 mg | 1000 cap pack varies | Professional Drug Store | 70.670 |
| Penamox 500 Capsules | Capsule (as Trihydrate) 500 mg | 500 cap pack varies | Hikma Pharmaceuticals Co.Ltd/Jordan | 74.830 |
| Ultramox Forte Cap | Capsule (as Trihydrate) 500 mg | 100x10 pack varies | The Arab Pharmaceutical Manufactruing Co. | 132.810 |